Panorama™
Use
Panorama™ is a noninvasive prenatal screening test (NIPT), using a blood-based SNP‑based technology to distinguish between maternal and fetal (placental) DNA, screening for chromosomal conditions that affect a baby's health including common trisomies (Trisomy 21, 18, 13), sex chromosome aneuploidies, triploidy, and selected microdeletions, with optional testing for fetal sex, zygosity, and fetal fraction as early as nine weeks of gestation. It is the only SNP‑based NIPT that can detect triploidy and differentiate DNA sources using >13K SNPs, validated in real‑world prospective studies with >99% sensitivity for trisomies and specific detection capabilities for 22q11.2 deletions. Panorama is a screening — not diagnostic — test; high-risk findings require confirmatory diagnostic testing such as CVS or amniocentesis. Panorama has been validated with full genetic confirmation, with zero fetal sex errors and high clinical sensitivity and PPV. Most results return within a defined timeframe after sample receipt. All decisions should involve consultation with healthcare providers. Panorama is CLIA‑certified, CAP‑accredited, ISO 13485‑certified, but not FDA‑cleared or approved. Panorama supports singleton and twin (some workflows), though some options may be unavailable for egg donor or gestational carrier pregnancies. Panorama™ screens multiple chromosomal conditions including trisomy 21/18/13, monosomy X, XXY, XXX, XYY, 22q11.2 deletion, Prader‑Willi syndrome, Angelman syndrome, 1p36 deletion, Cri‑du‑chat syndrome, and triploidy. Many conditions are detailed with background clinical context.
Special Instructions
Panorama™ uses an SNP‑based noninvasive cfDNA methodology and requires collection via Natera’s sample collection kit; accessible for both singleton and twin pregnancies, with unique workflows such as vanishing twin detection. Results return typically within 5–7 calendar days from sample receipt. The test is screening only; high‑risk results should be followed by diagnostic testing. Not cleared by FDA, but the lab is CLIA‑certified, CAP‑accredited, and ISO 13485‑certified. Some workflows (e.g., triploidy, microdeletions beyond 22q11.2) may be unavailable in certain twin or egg‑donor gestational contexts.
Limitations
Panorama™ is a screening (not diagnostic) test; high‑risk findings must be confirmed with diagnostic testing (e.g., CVS or amniocentesis). While validated for full‑region deletions in Prader‑Willi/Angelman syndromes, it may not detect smaller deletions or other molecular mechanisms such as UPD or methylation. The test is not FDA‑cleared or approved. Some options are unavailable in certain contexts: not validated for egg‑donor or gestational carrier pregnancies or in cases of dizygotic twins for detecting triploidy or microdeletions (except 22q11.2).
Methodology
NGS
Biomarkers
Result Turnaround Time
5-7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided